Aloperine suppresses LPS-induced macrophage activation through inhibiting the TLR4/NF-κB pathway
- 1 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Inflammation Research
- Vol. 69 (4), 375-383
- https://doi.org/10.1007/s00011-019-01313-0
Abstract
Objective The currently available anti-inflammatory drugs often cause diverse side effects with long-term use. Exploring anti-inflammatory drugs with better efficacy and lower toxicity presents an ongoing challenge. Aloperine is an alkaloid extracted from the leaves and seeds of Sophora alopecuroides L. However, the anti-inflammatory effects of Aloperine have not been fully elucidated. This study aimed to investigate whether Aloperine suppresses lipopolysaccharide (LPS)-induced inflammatory responses in RAW264.7 macrophages. Methods RAW264.7 macrophages were stimulated with LPS (1 mu g/mL) in the presence or absence of Aloperine (50 and 100 mu M). mRNA expression was measured by real-time PCR, and protein expression was assessed by western blot analysis. The secretion of pro-inflammatory cytokines was measured by ELISA. The levels of nitric oxide (NO) and reactive oxygen species (ROS) were measured by staining. The transcriptional activity of NF-kappa B was assayed by a luciferase activity assay. Results The results proved that Aloperine inhibited the expression of LPS-induced pro-inflammatory cytokines [tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-17A (IL-17A)] in macrophages. Treatment with Aloperine inhibited NO production through suppressing inducible nitric oxide synthase (iNOS) expression and the secretion of prostaglandin E-2 (PGE(2)) by inhibiting cyclooxygenase 2 (COX-2) expression. Aloperine prevented LPS-induced oxidative stress by reducing the generation of ROS. Furthermore, aloperine significantly reduced Toll-like receptor 4 (TLR4) and myeloid differentiation factor (Myd-88) levels and prevented the nuclear translocation of nuclear factor-kappa B (NF-kappa B) in LPS-treated macrophages. Conclusion Taken together, our findings show that Aloperine could suppress LPS-induced macrophage activation by inhibiting the TLR4/Myd-88/NF-kappa B pathway.Funding Information
- Key research fund of wannan medical college (WK2018ZF05)
This publication has 28 references indexed in Scilit:
- 7b, a novel naphthalimide derivative, exhibited anti-inflammatory effects via targeted-inhibiting TAK1 following down-regulation of ERK1/2- and p38 MAPK-mediated activation of NF-κB in LPS-stimulated RAW264.7 macrophagesInternational Immunopharmacology, 2013
- PF2401-SF, standardized fraction of Salvia miltiorrhiza shows anti-inflammatory activity in macrophages and acute arthritis in vivoInternational Immunopharmacology, 2013
- Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 PathwayMolecular Neurobiology, 2013
- Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other DiseasesPharmaceutical Research, 2008
- Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen speciesThe EMBO Journal, 2007
- Macrophage heterogeneity and tissue lipidsJCI Insight, 2007
- Monocyte and macrophage heterogeneityNature Reviews Immunology, 2005
- Many actions of cyclooxygenase‐2 in cellular dynamics and in cancerJournal of Cellular Physiology, 2002
- Molecular mechanisms of NF-κB activation induced by bacterial lipopolysaccharide through Toll-like receptorsInnate Immunity, 2000
- Expression and localization of COX-2 in human airways and cultured airway epithelial cellsEuropean Respiratory Journal, 1999